Forgot your password?
Positive topline results have been announced from an open-label phase 2 clinical trial (Study ‘207’) evaluating VDPHL01, an oral minoxidil formulation, for women with mild-to-moderate pattern hair loss.
The burden of diagnosed incident cases of melanoma in the US, France, Germany, Italy, Spain, the UK, Canada and Australia (the 8MM) is expected to increase at an annual growth rate (AGR) of 1.47%, from 229,000 in 2025 to 263,000 cases in 2035, forecasts GlobalData, an intelligence and productivity platform.
Sun Pharmaceutical industries’ (Sun Pharma) supplemental Biologics License Application (sBLA) for ILUMYA (tildrakizumab) to treat adults with active psoriatic arthritis (PsA) has been accepted for review by the US FDA.
Biogen’s AMETHYST phase 2/3 study (Part A) of litifilimab in people living with cutaneous lupus erythematosus (CLE) has shown positive results.
Arcutis Biotherapeutics has published data from the phase 3 open-label extension (OLE) study (INTEGUMENT-OLE) evaluating ZORYVE (roflumilast) in children aged two to five years with mild-to-moderate atopic dermatitis.
The National Institute for Health and Care Excellence (NICE) has released a draft scope of the Health Technology Evaluation (HTA) for the use of povorcitinib as a treatment for moderate-to-severe active hidradenitis suppurativa (HS) after a TNF-alpha inhibitor.
The American Academy of Dermatology (ADD) has published guidelines of care for the prevention and management of atopic dermatitis in paediatric patients.
Novartis’ Cosentyx (secukinumab) has received US FDA approval to treat paediatric patients aged 12 years and older with moderate-to-severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population.
Takeda has released the outcome of two phase 3 studies of zasocitinib (TAK-279) in adults with moderate-to-severe plaque psoriasis (PsO), with data presented at the 2026 American Academy of Dermatology (ADD) Annual Meeting.
UCB announced new data from the evaluation of BIMZELX (bimekizumab) at the 2026 American Academy of Dermatology (ADD) Annual Meeting in Denver, US.